Back to search

Article

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

2025-09-10

Abstract excerpt

Low grade serous ovarian cancer (LGSOC) accounts for ∼5% of all ovarian cancers, with >1,000 new cases diagnosed each year in the United States. Currently, there is no established standard-of-care treatment for this subtype, and chemotherapy response rates are only ∼4%. One defining characteristic of LGSOC is a high prevalence of mutations within the MAPK pathway, which has motivated studies using MEK inhibitors t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d99d9f98-e06b-55d3-b2bd-2576f7bfa98f
DOI
10.1101/2025.09.05.674550
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesDOI 10.1101/2025.09.05.674550
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic targetSemantic proximity
The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinomaSemantic proximity
NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK InhibitionSemantic proximity
Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient.Semantic proximity
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectivesSemantic proximity
Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Semantic proximity
Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity
Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutationSemantic proximity
Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic VulnerabilitySemantic proximity
Select a neighboring publication to make it the new centre.